Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05855083
Other study ID # OMS721-HCT-002
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 1, 2023
Est. completion date December 2025

Study information

Verified date November 2023
Source Omeros Corporation
Contact Omeros Clinical Trial Information
Phone 206-676-5000
Email ctinfo@omeros.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).


Description:

This is a Phase 2, uncontrolled, single-dosing regimen study in pediatric patients from 28 days to less than 18 years of age with high risk HSCT-TMA. At least 4 patients will be required from each of 3 age cohorts: 28 days to <2 years of age, 2 years to <12 years of age, and 12 years to <18 years of age. Treatment will be for 8 weeks and patients will be followed for up to 52 weeks.


Recruitment information / eligibility

Status Recruiting
Enrollment 18
Est. completion date December 2025
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 28 Days to 17 Years
Eligibility Inclusion Criteria: 1. Age at least 28 days and less than 18 years prior to informed consent (Visit 0). 2. Have informed consent from at least one parent or legal guardian as required by local law and regulation. Patient informed consent will be required if the patient has reached the local legal age of majority. 3. Assent from patients as required by local law and regulation. 4. Have received an allogeneic hematopoietic stem cell transplant for the treatment of benign or malignant disease. 5. Have a diagnosis of HSCT-TMA defined as meeting both of the following criteria: - Platelet count < 50,000/mL or a decrease in platelet count > 50% from the highest value obtained following transplant. - Evidence of microangiopathic hemolysis (presence of schistocytes, serum lactate dehydrogenase [LDH] > upper limit of normal ([ULN], or haptoglobin < lower limit of normal [LLN]) 6. Have at least one of the following HSCT-TMA high-risk criteria: - HSCT-TMA persistence > 2 weeks following modification of calcineurin inhibitors or sirolimus OR - Have evidence of high-risk HSCT-TMA defined as at least one of the following: - Spot protein/creatinine ratio > 2 mg/mg - Serum creatinine > 1.5 x the creatinine level prior to TMA development - Biopsy-proven gastrointestinal TMA - TMA-related neurological abnormality - Pericardial or pleural effusion without alternative explanation - Pulmonary hypertension without alternative explanation - Have Grade III or Grade IV graft-versus-host disease (GVHD) or, in the opinion of the Investigator, risk for development of Grade III or Grade IV GVHD if immunosuppression were to be modified - Have elevated serum C5b-9 (> 244 ng/mL) 7. If sexually active and of childbearing potential (for female pediatric patients, defined as starting at onset of menses), must agree to practice a highly effective method of birth control throughout study drug treatment and for at least 12 weeks after the last dose of study drug, such method of birth control defined as one that results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence (abstinence is acceptable when it is in line with the patient's preferred and usual lifestyle and is defined as complete abstinence of sexual intercourse, not periodic abstinence or withdrawal), or vasectomized partner. 8. Male patients must be willing to avoid fathering children for at least 12 weeks following the last dose of study medication. Exclusion Criteria: 1. All treatments for HSCT-TMA are allowed except eculizumab, ravulizumab, and defibrotide within 3 months prior to informed consent, unless failure of therapy can be documented. a. Patients may not be on eculizumab, ravulizumab, or defibrotide for any indication at screening. 2. Have Shiga toxin-producing Escherichia coli haemolytic uraemic syndrome (STEC-HUS). Test results obtained within 28 days prior to informed consent may be used. 3. Have ADAMTS13 activity < 10%. Test results obtained within 28 days prior to informed consent may be used. 4. Have a severe, uncontrolled systemic bacterial or fungal infection requiring antimicrobial therapy, or a severe uncontrolled viral infection (as determined by the investigator); prophylactic antimicrobial therapy administered as standard of care is allowed. 5. Have malignant hypertension (blood pressure [BP] > 99th percentile plus 5 mmHg with bilateral hemorrhages or "cotton-wool" exudates on fundoscopic examination). 6. Due to conditions other than HSCT-TMA, have a poor prognosis with a life expectancy of less than 3 months in the opinion of the Investigator. 7. If pregnant or lactating. 8. Have received treatment with an investigational drug or device within 4 weeks of entering study. 9. Have abnormal liver function tests defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 times ULN within 28 days prior to informed consent. 10. Have a positive test by antigen or polymerase chain reaction (PCR) for human immunodeficiency virus (HIV), if negative within 28 days prior to informed consent, the test does not need to be repeated. 11. Patient or one or more of the patient's parents or legal guardians are is an employee or an immediate family member of Omeros, the Clinical Research Organization (CRO), an Investigator, or a study staff member. 12. Have a known hypersensitivity to any constituent of the product. 13. Presence of any condition that the Investigator believes would put the patient at risk.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Biological: narsoplimab
Treatment with narsoplimab 4 mg/kg will be administered

Locations

Country Name City State
Germany Omeros Investigational Site Halle
Germany Omeros Investigational Site Hanover
Israel Omeros Investigational Site Haifa
Israel Omeros Investigational Site Jerusalem
Israel Omeros Investigational Site Ramat Gan
Israel Omeros Investigational Site Tel Aviv
Netherlands Omeros Investigational Site Utrecht
Spain Omeros Investigational Site Pamplona
United States Omeros Investigational Site Boston Massachusetts
United States Omeros Investigational Site Gainesville Florida
United States Omeros Investigational Site Houston Texas
United States Omeros Investigational Site New York New York
United States Omeros Investigational Site Saint Louis Missouri
United States Omeros Investigational Site San Diego California
United States Omeros Investigational Site Seattle Washington
United States Omeros Investigational Site Valhalla New York

Sponsors (1)

Lead Sponsor Collaborator
Omeros Corporation

Countries where clinical trial is conducted

United States,  Germany,  Israel,  Netherlands,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary 100-day survival rate following high-risk HSCT-TMA diagnosis. Percentage of patients alive at 100 days following the diagnosis of high-risk HSCT-TMA 100 days
Secondary Number of participants with treatment-emergent adverse events assessed by CTCAE v5.0 Number and percentage of patients with treatment-emergent adverse events will be summarized by MedDRA system organ class and preferred term 52 weeks
Secondary Percentage of patients meeting protocol definition of clinical response A responder is defined as a patient with HSCT-TMA who demonstrates improvement in laboratory TMA markers (platelet count and LDH) and clinical benefit (either improvement in organ function or reduction in transfusion burden) 52 weeks
Secondary 52 week survival rate following high-risk HSCT-TMA diagnosis Percentage of patients alive at 52 weeks following the diagnosis of high-risk HSCT-TMA 52 weeks
Secondary Overall survival following the diagnosis of high-risk HSCT-TMA Median overall survival (days) following the diagnosis of high-risk HSCT-TMA by Kaplan-Meier estimate 52 weeks
Secondary Pharmacokinetics (PK) of multiple-dose administration of OMS721 PK parameters including maximum concentration and minimum (trough) concentration 52 weeks
Secondary Presence of anti-drug antibody (ADA) Number and percentage of patient with at least one ADA positive sample 52 weeks
See also
  Status Clinical Trial Phase
Completed NCT00766883 - Problem-Solving Education for Caregivers and Patients During Stem Cell Transplant Phase 2
Recruiting NCT06148610 - Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients' Quality of Life and Support
Recruiting NCT04690933 - AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
Completed NCT02564458 - Fitness in Allogeneic Stem Cell Transplantation N/A
Recruiting NCT02543073 - MSC for Treatment of Interstitial Lung Disease After Allo-HSCT Phase 1/Phase 2
Not yet recruiting NCT01714557 - Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation N/A
Completed NCT00701688 - Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Phase 1
Completed NCT00023530 - Blood and Marrow Transplant Clinical Research Network N/A
Recruiting NCT04092309 - Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation N/A
Completed NCT00000603 - Cord Blood Stem Cell Transplantation Study (COBLT) Phase 2
Completed NCT02663622 - Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002) Phase 2
Recruiting NCT04937634 - Pharmacokinetic Study of Melphalan in Pediatric Hematopoietic Stem Cell Transplantation Phase 1
Recruiting NCT04203108 - ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis Phase 4
Completed NCT03654599 - Effects of Digital Stories Intervention on Psychosocial Well-being N/A
Withdrawn NCT03279133 - Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients. Phase 4
Completed NCT05151406 - Myths and Misconceptions About HSCT in a Limited Resource Region N/A
Completed NCT02241005 - Theraworx Bath Wipes Versus Standard Bath Wipes in the Reduction of Vancomycin-Resistant Enterococci N/A
Recruiting NCT03689465 - PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Phase 4
Recruiting NCT04868786 - Pharmacokinetics and Pharmacodynamics of Mycophenolate Mofetil in Pediatric Hematopoietic Stem Cell Transplantation Phase 1
Recruiting NCT03010579 - Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation Phase 4